173 related articles for article (PubMed ID: 34217677)
1. Dramatic Response to Convalescent Hyperimmune Plasma in Association With an Extended Course of Remdesivir in 4 B Cell-Depleted Non-Hodgkin Lymphoma Patients With SARS-Cov-2 Pneumonia After Rituximab Therapy.
Furlan A; Forner G; Cipriani L; Vian E; Rigoli R; Gherlinzoni F; Scotton P
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e731-e735. PubMed ID: 34217677
[TBL] [Abstract][Full Text] [Related]
2. Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies.
Magyari F; Pinczés LI; Páyer E; Farkas K; Ujfalusi S; Diószegi Á; Sik M; Simon Z; Nagy G; Hevessy Z; Nagy B; Illés Á
Ann Hematol; 2022 Oct; 101(10):2337-2345. PubMed ID: 35836007
[TBL] [Abstract][Full Text] [Related]
3. Clearance of the SARS-CoV-2 Virus in an Immunocompromised Patient Mediated by Convalescent Plasma without B-Cell Recovery.
Basheer M; Saad E; Laskar O; Schuster O; Rechnitzer H; Zisman-Rozen S; Azoulay D; Assy N
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445605
[TBL] [Abstract][Full Text] [Related]
4. Convalescent plasma and remdesivir for protracted COVID-19 in a patient with chronic lymphocytic leukaemia: a case report of late relapse after rapid initial response.
Schenker C; Hirzel C; Walti LN; Zeerleder SS; Andres M; Ramette A; Barbani MT; Suter-Riniker F; Holbro A; Tritschler T
Br J Haematol; 2022 Feb; 196(3):e27-e29. PubMed ID: 34458995
[No Abstract] [Full Text] [Related]
5. Sustained Response After Remdesivir and Convalescent Plasma Therapy in a B-Cell-Depleted Patient With Protracted Coronavirus Disease 2019 (COVID-19).
Malsy J; Veletzky L; Heide J; Hennigs A; Gil-Ibanez I; Stein A; Lütgehetmann M; Rosien U; Jasper D; Peine S; Hiller J; Haag F; Schmiedel S; Huber S; Jordan S; Addo MM; Schulze Zur Wiesch J
Clin Infect Dis; 2021 Dec; 73(11):e4020-e4024. PubMed ID: 33103195
[TBL] [Abstract][Full Text] [Related]
6. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019.
Martinot M; Jary A; Fafi-Kremer S; Leducq V; Delagreverie H; Garnier M; Pacanowski J; Mékinian A; Pirenne F; Tiberghien P; Calvez V; Humbrecht C; Marcelin AG; Lacombe K
Clin Infect Dis; 2021 Oct; 73(7):e1762-e1765. PubMed ID: 32986807
[TBL] [Abstract][Full Text] [Related]
7. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
Hopwood AJ; Jordan-Villegas A; Gutierrez LD; Cowart MC; Vega-Montalvo W; Cheung WL; McMahan MJ; Gomez MR; Laham FR
J Pediatric Infect Dis Soc; 2021 May; 10(5):691-694. PubMed ID: 33306130
[TBL] [Abstract][Full Text] [Related]
8. Persistent replication of SARS-CoV-2 in a severely immunocompromised patient treated with several courses of remdesivir.
Camprubí D; Gaya A; Marcos MA; Martí-Soler H; Soriano A; Mosquera MDM; Oliver A; Santos M; Muñoz J; García-Vidal C
Int J Infect Dis; 2021 Mar; 104():379-381. PubMed ID: 33359065
[TBL] [Abstract][Full Text] [Related]
9. Successful early treatment combining remdesivir with high-titer convalescent plasma among COVID-19-infected hematological patients.
Weinbergerova B; Mayer J; Kabut T; Hrabovsky S; Prochazkova J; Kral Z; Herout V; Pacasova R; Zdrazilova-Dubska L; Husa P; Bednar P; Ruzek D; Lengerova M
Hematol Oncol; 2021 Dec; 39(5):715-720. PubMed ID: 34396566
[No Abstract] [Full Text] [Related]
10. Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
Lancman G; Mascarenhas J; Bar-Natan M
J Hematol Oncol; 2020 Oct; 13(1):131. PubMed ID: 33008453
[TBL] [Abstract][Full Text] [Related]
11. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
Kenig A; Ishay Y; Kharouf F; Rubin L
Clin Immunol; 2021 Jun; 227():108723. PubMed ID: 33838340
[TBL] [Abstract][Full Text] [Related]
12. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19.
Hueso T; Pouderoux C; Péré H; Beaumont AL; Raillon LA; Ader F; Chatenoud L; Eshagh D; Szwebel TA; Martinot M; Camou F; Crickx E; Michel M; Mahevas M; Boutboul D; Azoulay E; Joseph A; Hermine O; Rouzaud C; Faguer S; Petua P; Pommeret F; Clerc S; Planquette B; Merabet F; London J; Zeller V; Ghez D; Veyer D; Ouedrani A; Gallian P; Pacanowski J; Mékinian A; Garnier M; Pirenne F; Tiberghien P; Lacombe K
Blood; 2020 Nov; 136(20):2290-2295. PubMed ID: 32959052
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
Rnjak D; Ravlić S; Šola AM; Halassy B; Šemnički J; Šuperba M; Hećimović A; Kurolt IC; Kurtović T; Mačak Šafranko Ž; Polančec D; Bendelja K; Mušlin T; Jukić I; Vuk T; Zenić L; Artuković M
Transfus Clin Biol; 2021 Aug; 28(3):264-270. PubMed ID: 33901641
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 pneumonia in a patient with granulomatosis with polyangiitis on rituximab: case-based review.
Rodriguez-Pla A; Vikram HR; Khalid V; Wesselius LJ
Rheumatol Int; 2021 Aug; 41(8):1509-1514. PubMed ID: 34091704
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of COVID-19 infection with convalescent plasma in B-cell-depleted patients may promote cellular immunity.
Kremer AE; Kremer AN; Willam C; Völkl S; Verhagen J; Achenbach S; van der Meijden ED; Lang V; Aigner M; Maier C; Tenbusch M; Korn K; Lutzny-Geier G; Spoerl S; Strauß R; Vetter M; Überla K; Neurath MF; Mackensen A; Schiffer M; Hackstein H
Eur J Immunol; 2021 Oct; 51(10):2478-2484. PubMed ID: 34350584
[TBL] [Abstract][Full Text] [Related]
16. Suboptimal response to combination therapy with tixagevimab/cilgavimab and remdesivir for persistent SARS-CoV-2 infections in immunocompromised patients.
Wu TY; Chen PY; Wang JT; Liu WD; Chen YC; Chang SC
J Antimicrob Chemother; 2024 May; 79(5):1196-1200. PubMed ID: 38538154
[No Abstract] [Full Text] [Related]
17. Treatment of chronic or relapsing COVID-19 in immunodeficiency.
Brown LK; Moran E; Goodman A; Baxendale H; Bermingham W; Buckland M; AbdulKhaliq I; Jarvis H; Hunter M; Karanam S; Patel A; Jenkins M; Robbins A; Khan S; Simpson T; Jolles S; Underwood J; Savic S; Richter A; Shields A; Brown M; Lowe DM
J Allergy Clin Immunol; 2022 Feb; 149(2):557-561.e1. PubMed ID: 34780850
[TBL] [Abstract][Full Text] [Related]
18. A 63-Year-Old Woman with a History of Non-Hodgkin Lymphoma with Persistent SARS-CoV-2 Infection Who Was Seronegative and Treated with Convalescent Plasma.
Moore JL; Ganapathiraju PV; Kurtz CP; Wainscoat B
Am J Case Rep; 2020 Oct; 21():e927812. PubMed ID: 33009361
[TBL] [Abstract][Full Text] [Related]
19. Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.
Trkulja V
Eur J Clin Pharmacol; 2021 Jun; 77(6):935-937. PubMed ID: 33404753
[No Abstract] [Full Text] [Related]
20. Successful Treatment of Persistent SARS-CoV-2 Infection in a B-Cell Depleted Patient with Activated Cytotoxic T and NK Cells: A Case Report.
Jassem J; Marek-Trzonkowska NM; Smiatacz T; Arcimowicz Ł; Papak I; Jassem E; Zaucha JM
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
